Recommendations for a national agenda to substantially reduce cervical cancer

Jennifer S. Smith, Noel T. Brewer, Debbie Saslow, Kenneth Alexander, Mildred R. Chernofsky, Richard Crosby, Libby Derting, Leah Devlin, Charles J. Dunton, Jeffrey Engle, Maria Fernandez, Mona Fouad, Warner Huh, Walter Kinney, Jennifer Pierce, Elena Rios, Mitchel C. Rothholz, Judith C. Shlay, Rivienne Shedd-Steele, Sally W. VernonJoan Walker, Theresa Wynn, Gregory D. Zimet, Baretta R. Casey

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Purpose: Prophylactic human papillomavirus (HPV) vaccines and new HPV screening tests, combined with traditional Pap test screening, provide an unprecedented opportunity to greatly reduce cervical cancer in the USA. Despite these advances, thousands of women continue to be diagnosed with and die of this highly preventable disease each year. This paper describes the initiatives and recommendations of national cervical cancer experts toward preventing and possibly eliminating this disease. Methods: In May 2011, Cervical Cancer-Free America, a national initiative, convened a cervical cancer summit in Washington, DC. Over 120 experts from the public and private sector met to develop a national agenda for reducing cervical cancer morbidity and mortality in the USA. Results: Summit participants evaluated four broad challenges to reducing cervical cancer: (1) low use of HPV vaccines, (2) low use of cervical cancer screening, (3) screening errors, and (4) lack of continuity of care for women diagnosed with cervical cancer. The summit offered 12 concrete recommendations to guide future national and local efforts toward this goal. Conclusions: Cervical cancer incidence and mortality can be greatly reduced by better deploying existing methods and systems. The challenge lies in ensuring that the array of available prevention options are accessible and utilized by all age-appropriate women - particularly minority and underserved women who are disproportionately affected by this disease. The consensus was that cervical cancer can be greatly reduced and that prevention efforts can lead the way towards a dramatic reduction in this preventable disease in our country.

Original languageEnglish
Pages (from-to)1583-1593
Number of pages11
JournalCancer Causes and Control
Issue number8
StatePublished - Aug 2013

Bibliographical note

Funding Information:
Conflict of interest The Cervical Cancer-Free America launch meeting was funded by unrestricted gifts from GlaxoSmithKline, Hologic, Qiagen, and Merck Corporation. Dr. Noel T. Brewer has received research grants, served on paid advisory boards, and/or been a paid speaker for Merck and GSK. Dr. Kenneth Alexander serves on the speakers Bureau for Merck vaccines, has spoken on behalf of MSD (Merck’s European branch), for Sanofi, and also serves as a paid advisor for Merck vaccines. Dr. Richard Crosby has received research grants and been a paid advisor for Merck. Dr. Warner Huh has served as a consultant for Roche Diagnostics, Merck Corporation, and GlaxoSmithKline. Dr. Gregory D. Zimet is an investigator on research grants funded by Merck’s Investigator Initiated Science Program (MISP). Dr. Jennifer Smith has received research grants, unrestricted educational gifts, served on advisory boards, and/or has been a paid speaker for GSK, Hologic Gen-Probe, Merck and QIAGEN.


  • Cervical cancer prevention
  • HPV test
  • HPV vaccine
  • Human papillomavirus
  • Pap test

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Recommendations for a national agenda to substantially reduce cervical cancer'. Together they form a unique fingerprint.

Cite this